GP IIb/IIIa inhibitors for STEMI: still the gold standard or an old survivor?
2012
Glycoprotein (GP) IIb\IIIa receptor plays a central role on platelets activation and its blockage has been a matter
of interest since the beginning of percutaneous revascularization. After first promising trials, GP IIb\IIIa inhibitors
(GPI) have been widely used in cath labs for about a decade, significantly improving prognosis for patients with STSegment
Elevation Myocardial Infarction (STEMI). However, their utilization isn’t exempt from risks, mainly in form of
bleeding disorders, which can negatively affect patients’ outcome. Moreover, routinary administration of thyenopiridines
like clopidogrel and the introduction of new anticoagulants like bivalirudin significantly reduced indications for GPI. In
this review, a risk/benefit evaluation GP IIb\IIIa inhibitors is presented and their indications for STEMI patients addressed
to revascularization are discussed according to recent advances reported in literature.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
1
Citations
NaN
KQI